Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Follicular Lymphoma Endometrial Cancer Be willing and able to provide written informed consent for the trial Be 18 years of age or older on day of signing informed consent For lymphoma, patients should have measurable disease based on the Lugano Criteria For FL patients must have received at least two lines of prior therapy. There is no upper limit for the number of prior therapies. Tumor tissues of all patients are encouraged to be submitted (optional) prospectively for whole or targeted exome sequencing of key cancer related genes, using the Columbia Combined Cancer Panel (CCCP) or a comparable sequencing platform, such as the MSK-IMPACT 468-gene oncopanel For EC the patients must have recurrent/advanced tumor for which surgical or the systemic curative treatments, or standard therapeutic approaches are not available. The following histologic subtypes are eligible: endometrioid, serous, clear cell, undifferentiated /dedifferentiated, mucinous, squamous, transitional, not-otherwise specified, and mixed celltype Fresh and or archived tumor tissues must be available to (a) establish the diagnosis of the respective malignancies as described in and (b) be investigated for biomarkers. Patients without historical material or fresh tissue biopsy that is adequate for both diagnosis and correlative studies will not be eligible for the clinical trial Left Ventricular Ejection Fraction (LVEF) > 50% A performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale Demonstrate adequate organ function. All screening labs should be performed within 14 days of treatment initiation HIV positive patients will be eligible as long as the viral load by polymerase chain reaction (PCR) testing is undetectable  The following treatments are prohibited: (a) Chemotherapy (including PI3K inhibitors and other approved or investigational drugs) and monoclonal antibody within 3 weeks; (b) radiotherapy within 2 weeks prior to entering the study; (c) systemic steroids that have not been stabilized (≥ 5 days) to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs Patients that have not recovered from adverse events due to chemotherapy agents administered more than 3 weeks earlier Hypersensitivity to copanlisib or any of its excipients Type I diabetes Uncontrolled Type II diabetes mellitus (HbA1c> 7.5%) Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin Patients that received major surgery and have not recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy Patients with active, clinically serious infections > CTCAE version 5 Grade 2 Patients with known active concurrent malignancy with the following exception: nonmelanoma skin cancer, prostatic intraepithelial neoplasia, or carcinoma in situ of the cervix, prostate cancer that responds to androgen deprivation therapy and has no progression of disease for at least 12 months. If there is a history of prior malignancy, the patient must be disease-free for ≥ 3 years Uncontrolled hypertension, i.e., blood pressure (BP) of ≥ 150/90; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other criteria